Previous 10 | Next 10 |
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action PR Newswire – IMU-856 is an Orally Available, Systemically Acting, Highly Selective and Potent Small Molecule Modulator of SIRT6 –...
--News Direct-- Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at restoring healthy gut function. The molecule has shown promise in treating c...
2023-05-04 08:07:28 ET Immunic ( NASDAQ: IMUX ) reported data from part C portion of its phase 1 trial of IMU-856 in patients with celiac disease. Celiac disease is a chronic digestive and immune disorder which damages the small intestine. The disorder is an immune reaction to e...
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders PR Newswire – Positive Effects Demonstrated Over Placebo in Four Key ...
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. PR Newswire – Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK , Apr...
Immunic to Participate in Investor and Scientific Conferences in May PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies fo...
(NewsDirect) Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). Vitt descri...
2023-04-05 10:07:20 ET Gainers: Liminal BioSciences ( LMNL ) +81% . InflaRx ( IFRX ) +51% . 180 Life Sciences ( ATNF ) +26% . YS Biopharma ( YS ) +22% . Immunic ( IMUX ) +21% . Losers: Bullfrog AI ( BFRG ) -15% ....
2023-04-05 07:52:14 ET Immunic ( NASDAQ: IMUX ) reported 50-week data from a maintenance phase of a phase 2b trial of vidofludimus calcium (IMU-838) to treat patients with moderate-to-severe ulcerative colitis (UC) and noted that it would deprioritize izumerogant (IMU-935) program. ...
2023-03-06 15:07:51 ET Another week of trading is underway and marks the first full week of March 2023. Whether you’re trading penny stocks or searching for the next mega-cap tech stocks to buy, research is the first place to begin the trading journey. Obviously, when it comes to che...
News, Short Squeeze, Breakout and More Instantly...
Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President,...
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...